The anti-CGRP fremanezumab (Ajovy) has finally been listed on the PBS, but the tight criteria for subsidy may deny access for many chronic migraine patients, according to some advocates. From 1 August, neurologist-treated patients averaging 15 or more headache days per month, with at least eight days of migraine, can access fremanezumab via the PBS, ...
Second CGRP antagonist, fremanezumab, listed on PBS for migraine
By Natasha Doyle
3 Aug 2021